MarketPulse

osteogenesis imperfecta

42 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Schall Law Firm

Ultragenyx Faces Class Action Over OI Drug Trial Misstatements

Ultragenyx faces class action lawsuit alleging false statements about its osteogenesis imperfecta drug's efficacy after Phase III trial failed to meet primary endpoint.
RAREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Mereo BioPharma Investors Face April Deadline in Securities Lawsuit Over Failed Trials

Investors in Mereo BioPharma face April deadline in class action lawsuit alleging executives misrepresented clinical trial results for setrusumab drug, causing stock losses.
MREOsecurities class actionmisleading statements